EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Limitations in the clinical translation of mesenchymal stromal cells: standardisation, heterogeneity and the recipient

Anna Etzenberger, Diana Hernandez

Frontiers in Cell and Developmental Biology · 30.04.2026 · 14

DOI: 10.3389/fcell.2026.1824475 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 30.04.2026. Verfasst von Anna Etzenberger und 1 weiteren Autor:innen. Beteiligte Einrichtung: Anthony Nolan Research Institute, Immunotherapy, London, United Kingdom. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anthony Nolan Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic efficacy of Mesenchymal Stromal Cells (MSCs) has been demonstrated in a multitude of pre-clinical studies and clinical trials, yet the translation of MSC therapies is limited by biological factors such as inter- and intra-donor variability in the function, differentiation capacity and proliferation rate of MSCs, as well as extrinsic factors such as the implementation of standardised reporting and characterisation guidelines. The complex relationship between MSC heterogeneity and recipient heterogeneity further contributes to the challenging interpretation of results and complicates the comparison of outcomes between studies. Efforts to enhance the therapeutic efficacy of MSCs have been made, however only a few focus on addressing heterogeneity. Aside from this, a clear understanding of the mechanism of action of MSCs and the development of appropriate functional/potency assays could aid in the standardisation of MSC therapies and provide information for the stratification of recipients. This review discusses the challenges associated with the clinical translation of MSCs and critically evaluates recent advancements in the strategies to enhance the therapeutic efficacy of MSCs.

Schlagwörter

Stichwörter der Autor:innen

Mesenchymal stromal cellscell heterogeneitycell therapyclinical trialsimmunology

Autor:innen und Institutionen

  • Anthony Nolan Research Institute, Immunotherapy, London, United Kingdom.
  • Cancer Institute, University College London, London, United Kingdom.

Förderung

  • Anthony Nolan Research Institute

Zitieren

APA

Etzenberger, A., & Hernandez, D. (2026). Limitations in the clinical translation of mesenchymal stromal cells: standardisation, heterogeneity and the recipient. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1824475

Vancouver

Etzenberger A, Hernandez D. Limitations in the clinical translation of mesenchymal stromal cells: standardisation, heterogeneity and the recipient. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1824475

BibTeX
@article{Etzenberger2026,
  author = {Etzenberger, Anna and Hernandez, Diana},
  title = {Limitations in the clinical translation of mesenchymal stromal cells: standardisation, heterogeneity and the recipient},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2026},
  volume = {14},
  doi = {10.3389/fcell.2026.1824475}
}
Kostenlos starten →